CD22 Antibody

CD22 Antibody Datasheet

CD22 Antibody Product Information

• Immunogen: Recombinant Human CD22 protein (Catalog#11958-H08H)
• Antibody Type: Mouse Monoclonal Antibody ( Mouse mAb Service Platform )
• Clone ID: 07
• Ig Type: Mouse IgG1
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD22 (rh CD22; Catalog#11958-H08H; P20273-1; Met 1-Arg 687). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.

CD22 Antibody Usage Guide

• Specificity: Human CD22
• No cross-reactivity in ELISA with

  Human cell lysate (293 cell line)

• Direct ELISA: This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human CD22. The detection limit for Human CD22 is approximately 0.078 ng/well.
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

CD22 Antibody Background

CD22 is a molecule belonging to the immunoglobulin superfamily, SIGLEC (sialic acid binding Ig-like lectin) family. It is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The CD22 cell-surface adhesion molecule is capable of modulating B lymphocyte antigen receptor (BCR)-mediated signals, as well as the generation of BCR-independent signals. CD22 is an inhibitory coreceptor of the B-cell receptor (BCR), and plays a critical role in establishing signalling thresholds for B-cell activation. CD22 recruits the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits B-cell receptor (BCR)-induced Ca2+ signaling on normal B cells. CD22 interacts specifically with ligands carrying alpha2-6-linked sialic acids. Interaction of CD22 to ligands in trans can regulate both B-cell migration as well as the BCR signaling threshold. However, a more complex role for CD22 has recently emerged, including a central role in a novel regulatory loop controlling the CD19/CD21-Src-family protein tyrosine kinase (PTK) amplification pathway that regulates basal signaling thresholds and intensifies Src-family kinase activation after BCR ligation. CD19 regulates CD22 phosphorylation by augmenting Lyn kinase activity, while CD22 inhibits CD19 phosphorylation via SHP-1. Thus, the CD19/CD22 loop may be a potential therapeutic target in autoimmune disease for modulating B cell signaling.

References

1. Sato S. et al., 1998, Semin Immunol. 10 (4): 287-97.
2. Walker JA. et al., 2008, Immunology. 123 (3): 314-25.
3. Nitschke L. 2009, Immunol Rev. 230 (1): 128-43.
4. Tedder TF. et al., 2005, Adv Immunol. 88: 1-50.
5. Fujimoto M. et al., 2007, J Dermatol Sci. 46 (1): 1-9.